Skip to main content

Table 1 All of the involved markers in CRC susceptibility among the Iranian patients

From: Genetic and molecular origins of colorectal Cancer among the Iranians: an update

STUDY (ET AL) Year Gene population Results
Nomani [14] 2005 GST 39 controls
60 patients
Over activity in tumors
Ebrahimkhani [15] 2012 GSTT1 100 controls
100 patients
Polymorphism was correlated with CRC risk
Jamhiri [16] 2017 SOD1 239 controls
204 patients
Polymorphism was correlated with CRC risk
Mokarram [19] 2015 UBE2Q1 50 controls
60 patients
Hyper Methylation
Mokarram [19] 2015 UBE2Q2 50 controls
60 patients
Un methylation and stage of tumor
Amirghofran [22] 2009 TGFB1 138 controls
134 patients
Polymorphism was correlated with CRC risk
Damavand [24] 2015 SMAD7 253 controls
234 patients
Polymorphism was correlated with CRC risk
Naghibalhossaini [29] 2012 AXIN2 170 controls
112 patients
Methylation with stage and sex
Samaei [30] 2014 APC, AXIN2, DKK3, SFRP2, 4, 5, WIF1, and WNT5a 125 N/Ta Methylation
Naini [31] 2016 SFRP2 25 controls
48 polyps
Hyper Methylation as precancerous marker
Nemati [34] 2015 IL-17A 203 controls
202 patients
Polymorphism was correlated with CRC risk
Azimzadeh [38] 2011 IL-16 405 controls
260 patients
Polymorphism was correlated with CRC risk
Al-Samadi [39] 2016 IL-17F 10 tumors Under expression in tumors
Ahangari [42] 2014 NOD2 88 controls
88 patients
Polymorphism was correlated with CRC risk
Azimzadeh [43] 2013 CD86 150 controls
150 patients
Polymorphism was correlated with CRC risk
Abtahi [44] 2017 IL-10 30 controls
58 patients
Lower levels in CRC patients
Habibollahi [49] 2010 COX2, iNOS 17 patients Correlation with lymph node metastasis
Hadinia [52] 2007 CTLA4 190 controls
109 patients
Polymorphism was correlated with CRC risk
Shafaei [53] 2013 CD166 121 N/T Correlation with tumor location
Mahmoudi [56] 2016 ADIPOQ, ADIPOR1 339 controls
261 patients
Polymorphism was correlated with CRC risk
Motlagh [58] 2007 EGFR 34 N/T Marker of preoperative therapy response
Tavangar [59] 2005 HER2 55 N/T Correlation with tumor size, stage, differentiation
Orang [61] 2014 STYK1/NOK 40 N/T Correlation with tumor size, stage
Tavakoli Koudehi [63] 2018 AKAP4 62 N/T Correlation with liver metastasis in CRC patients
Hamzehzadeh [65] 2018 KRAS 87 patients Mutation
Koochak [68] 2016 KRAS 1000 patients Correlation with age, tumor type
Omidifar [69] 2015 KRAS 100 patients Mutation
Ghavam-Nasiri [71] 2007 P53 100 patients Correlation with stage
Asadi [74] 2018 CASPASE3 50 N/T Under expression
Golmohammadi [75] 2013 P53 61 patients Correlation with distal tumors, sex, survival
Moossavi [77] 2018 VDR 100 controls
100 patients
Polymorphism was correlated with CRC risk
Mahmoudi [78] 2010 VDR 180 controls
160 patients
Polymorphism was correlated with CRC risk
Mahmoudi [82] 2016 IRS1 438 controls
312 patients
Polymorphism was correlated with CRC risk
Karimi Mazraehshah [86] 2018 miR-200c, BMI1 38 controls
38 patients
Under an over expression, respectively
Orang [90] 2014 miR-205 36 N/T Correlation with lymph node metastasis, stage
Basati [91] 2014 miR-21 40 controls
40 patients
Correlation with stage
Bastaminejad [92] 2017 miR-21 40 controls
40 patients
Correlation with stage
Basati [95] 2016 miR-194 55 controls
55 patients
Correlation with stage
Eslamizadeh [105] 2018 miR-135b, 20a, 31, 21 32 controls
74 patients
Increased levels in CRC patients
Montazer Haghighi [107] 2009 MMR 248 controls
592 patients
Novel mutations in PMS2 and MLH1
Shahmoradi [108] 2012 hMLH1 20 patients Novel mutations
Moghbeli [110] 2011 MMR 67 N/T MSI was correlated with location, stage, lymph node metastasis
Faghani [111] 2012 MMR 96 N/T MSI was correlated with location
Nazemalhosseini Mojarad [112] 2016 MMR 158 N/T MSI was correlated with differentiation, stage, sex
Brim [113] 2008 MMR 53 patients MSI was correlated with differentiation
Khatami [114] 2009 MGMT 213 controls
208 patients
Polymorphism was correlated with CRC risk
Farzanehfar [115] 2013 MGMT 40 N/T Methylation
Nemati [117] 2018 HDAC3 48 N/T Correlation with stage, differentiation
Ayoubi [121] 2017 H3.3B 36 N/T Correlation with stage, lymph node
Mohammed [125] 2015 tRNALeu(CUN) 100 controls
30 patients
Mutation
Haghighi [128] 2008 MTHFR 239 controls
227 patients
Polymorphism was correlated with CRC risk
Naghibalhossaini [131] 2010 MTHFR 231 controls
175 patients
Polymorphism was correlated with CRC risk
Samanian [136] 2011 MDR1 60 controls
60 patients
Correlation with grade
Khedri [137] 2011 MDR1 137 controls
118 patients
Correlation with stage
Ardalan Khales [138] 2015 SALL4 111 N/T Correlation with grade, depth of invasion
Raeisossadati [143] 2014 DPPA2, HIWI 46 N/T Correlation with stage, lymph node metastasis
Mirzaei [146] 2015 LGR5, DCLK1 58 controls
58 patients
Correlation with stage
Niknami [149] 2017 FIBRONECTIN 45 patients Correlation with grade
Hosseini [150] 2018 NEBL 67 N/T Correlation with lymph node metastasis
Behrouz Sharif [153] 2016 SEPT9 45 N/T Methylation
Raeisossadati [154] 2011 CEA, TEM8 40 controls
40 patients
Over expression in CRC patients
  1. aTumor tissues and normal margins